TRIPS and Pharmaceutical Industry: Issues of Strategic Importance

N. Lalitha

Gujarat Institute of Development Research
Gota, Ahmedabad 380 060

November 2001
Abstract

Trade Related Intellectual Property Rights (TRIPS) brings in uniformity in the standards of intellectual property rights among the member countries of the WTO irrespective of their developmental status. While this is expected to result in free flow of technology and investment among the member countries, yet the extent to which the benefits will accrue depend on the domestic industry and the developmental status of the country that is undertaking the reform measures. Viewed from this angle, India with its fairly developed pharmaceutical industry can benefit by suitably modifying its patent law. Further, the industry by strengthening its R&D, besides focusing on new product development can also benefit as a contract researcher and manufacturer.

JEL Classification : 034 and L65

Keywords : Intellectual Property Rights; Patents; Pharmaceutical Industry

Acknowledgements

I thank Dr. Harish Padh, Director, B V Patel Pharmaceutical Education Research and Development Centre, Ahmedabad, for the stimulating discussion on some of the issues discussed in this paper and the referee of this paper for his comments. My sincere thanks are also due to Dr. Uma Rani, Co-ordinator of the working paper series GIDR for her efforts in bringing out this paper as a working paper of GIDR. Ms.Sheela and Ms. Girija helped in word processing the paper. The usual disclaimers apply.
1. INTRODUCTION

Trade Related Intellectual Property Rights (TRIPS) were brought in with the purpose of universalising the standards of Intellectual Property Rights and frame the rules of the game of the developing countries on par with the developed countries. Several factors like the continuous advancement in science, new breakthroughs in bio-technology, the growing participation of the private sector in the cost intensive research and development in the knowledge based pharmaceutical sector and the relative strength demonstrated by the developing nations in adapting the results of the scientific innovations to the local environment have prompted the industrialized nations to seek stronger protection for their innovations in all the countries. The scenario now is that through the Uruguay Round, the developed countries have forced the developing countries to comply with the TRIPS agreement after they had attained a high level of technological and industrial capability while the developing countries are yet to reach that position.

The Paris convention of 1883, one of the oldest treaties governing the protection of industrial intellectual property was revised up to 1967. The Paris Convention was fairly liberal in protecting the Intellectual Property Rights (IPR). Under this convention, member countries were free to determine the standards of protection, the subject matter of protection and the period of protection and thus maximum divergence were observed in the case of protection of innovations in the pharmaceutical sector. Several countries fearing that the patent protection in pharmaceuticals will limit the spread of knowledge and thus prevent the scientific innovations reaching the general and the needy public, neither protected the processes of manufacturing a drug nor the final drug. This is because, once a product is patented (product patents), the same product cannot be produced by an alternate method or process during the protection period. However, if the process alone is protected (process patents), then an alternative process which
is mostly `invented' in line with the earlier process could be used to produce the same product, since in pharmaceuticals, a product can be produced by more than one way. Differences were observed in the term and duration of protection too. For instance, while some countries granted protection from the date of filing the patent application yet others did so from the date of the grant of patent. Many developed countries had a period of protection that ranged from 14 to 16 years. Costa Rica had a patent term of one year. While the US and Japan provided protection for a period of 17 years from the date of grant, Australia and UK provided protection from the date of filing. Turkey abolished both product and process patents in 1961 and Germany adopted product patents in 1968. Japan started with product patent system in 1975. Neither the process nor the product is protected in Italy. In Europe both products and process are protected for a period of 20 years. Mexico abolished protection in the 1970s, however reformed the system in the early 90s, which is almost equivalent to the system prevalent in the developed countries. The Soviet Union and China instituted many elements for an effective intellectual property system in the ‘80s even before their admission in to the WTO. Brazil recognised product patents only in the mid ‘90s after much arm-twisting by the US. However, intellectual property protection among different countries shows a remarkable change between the ‘80s and the ‘90s. Canada and Denmark adopted product patents in 1983, Austria in 1987 and Spain, Portugal, Greece and Norway, adopted the same in 1992. Some of the developing countries like Sri Lanka, Philippines, have already provided product patents. Neighbouring Pakistan also adopted process patents with a longer duration of 16 years. However, now Pakistan has complied with TRIPS requirements. The product patents protection in Pakistan now includes any substance, article, apparatus, machine or a clinical product. The term of the patent has been extended to 20 years (Intellectual Property Rights, March-April, 2001).

Thus, while many of the industrially developed resource rich countries chose to reward the innovators and adopted product patents to promote further innovations, some of the developing countries realised the potential of the process patents in developing the domestic industry and adopted the same. Thus, the developing countries with process patent protection were able to take

---

1 This discussion draws from Lanjouw (2000) and Watal (2001).
advantage of the innovations made by early innovators. When a subsequent product is based on an innovation made earlier, the late entrant enjoys the reduction in the cost of developing the product without of course sharing the benefits/profits derived by the new product with the early innovator. But the capacity to exploit the earlier innovations to its advantage depends on the technological development of the country, capacity of the domestic industry, the market size and the type of technology that is used in developing the product. Of the many countries that adopted process patents, developing countries like India, China, Korea and Brazil have developed expertise to develop new products, which were mostly around the earlier innovations of the developed countries. It is assessed that the deficiencies in India’s intellectual property system alone are estimated to cost US companies around $500 million a year (Scrip’s Year Book, 2000).

As per the minimum standards mentioned in the TRIPS agreement, `patent shall be granted for any inventions, whether products or processes, in all fields of technology provided they are new, involve an inventive step and are capable of industrial application without any discrimination to the place of invention or to the fact that products are locally produced or imported. Accordingly, now patents will have to be granted in all areas including pharmaceuticals and the effective period of protection is for twenty years from the date of filing the application. With the implementation of TRIPS agreement by most of the developing countries by 2005, a stronger patent regime or product patents will be uniformly applicable on the pharmaceutical innovations among the member countries² of the World Trade Organisation.

However, in order to smoothen out the differences in the level of protection and to make necessary amendments in the national laws to adopt product patents, countries with different developmental status have been given a transitional period to bring in reforms in the desired areas and make the laws comparable with other countries. India has to enforce the system of stronger patents from January 2005. During the transitional period of 1995-2005, India has to start accepting applications for product patents from 1995 and provide exclusive

² In late ‘90s, as many as 140 countries were members of the WTO.
marketing rights (EMR) for the products that were granted patent protection elsewhere.

Within India, the opinion on stronger patents on the pharmaceutical industry is divided, some emanating from the country’s prior experience with product patents and others from countries, which have recently adopted product patents. These evidences suggest that a country’s level of IPR influences a variety of social and economic factors which range from common peoples access to medicine to the functioning of the domestic industry, the investment in R&D, technology etc. Initially India was very apprehensive of the stronger protection in pharmaceutical industry which is expressed sharply by Mrs. Indira Gandhi as `the idea of a better –ordered world is one in which medical discoveries will be free of patents and there will be no profiteering from life and death’. Developing countries particularly, India, Argentina and Brazil were the strongest opponents of the TRIPS agreement and India was more vocal in voicing her views on issues raised by the developed countries. Now due to pressures from various quarters, all the three countries have accepted the TRIPS agreement and India currently looks for flexibility within the TRIPS framework that would have positive impact on the people, industry and economy.

The universal TRIPS regime is expected to result in free flow of trade, investment and technical know-how among the member countries by resolving the barriers that exist in the form of differences in the standards of intellectual property. There is a rich amount of literature available, which has looked into the various impacts of universal IPR regime.

In this paper a modest attempt is made to highlight the issues of relevance for India that emerge from various studies on the probable impact of product patents on the pharmaceutical industry and also present some of the important provisions within the TRIPS agreement that are favourable for developing countries like India. These are presented in sections 2 and 3. The last section presents the future scenario of the pharmaceutical industry.
2. PRODUCT PATENTS AND ISSUES OF STRATEGIC RELEVANCE

Of all the aspects of Intellectual Property Rights, patents in the pharmaceutical sector have evoked considerable academic debate. In the following paragraphs issues concerning the welfare of the people, R&D, foreign direct investment and technology transfer are addressed.

2.1 Prices of the Medicines

Much of the debate on the impact of product patents on the pharmaceutical industry in India has centred on the issues of price of the patented product and their accessibility. While it is true that a positive association is observed between stronger protection and prices of drugs, it is also true that prices decline with the expiry of patent. In the US, Frank and Salkever (1995) report a rapid reduction in the price of drugs after the expiration of the patent. Though more competition among generic drug producers results in substantial price reductions for those drugs, yet increased competition from generics does not result in aggressive response in price behaviour by established brand name products. Danson and Chao (2000) on the contrary observe that generic competition has a significant negative effect on price for the US and other countries with relatively free pricing like UK, Germany and Canada, whereas for the countries with strict price regulation like France, Italy and Japan the number of generic competitors has either no effect or a positive effect on prices.

In India when amoxycilin was first introduced by a multinational the price of the drug was very high. However, with the local manufacturers stepping in to produce the indigenous version of the amoxycilin, the price of the same declined rapidly. It should be admitted that adoption of the process patents along with the domestic regulations that restricted the role of the multinationals resulted in the growth of the domestic industry. The number of pharmaceutical manufacturers increased from a mere 200 in 1950-51 to more than 6000 in the ‘80s, which reached a phenomenal figure of 23790 in 1998-99. Of this a sizeable percentage of firms belong to the small-scale sector. It is estimated that out of the 28.6 million workforce in the pharmaceutical industry, about 4.6 million is employed in the organised units and the rest are engaged in distribution and ancillary industry. These units produce drugs that are not under patent protection and are
analogous to products that are already there in the market. Hence competition is severe among the pharmaceutical units in India, which is one of the important reasons for the relatively lower prices of the medicines in India.

Irrespective of the competition, because of the socio-welfare implication of the pharmaceutical prices, all over the world other than in the US, the prices of medicines are subject to government regulations. However, the methods used to regulate prices differ from country to country. In USA and Canada, the cost is charged in full to patients. Even in the US, a law allowing the pharmacists to import the drugs from Canada that would be cheaper by 30-50 per cent was proposed but was not passed due to pressures mainly from the industry quarters (San Francisco Chronicle, January 1, 2001). Industry observers however note that the high rates of return made possible by the free pricing policy of the US government are responsible for half of the new drugs that are invented there. In some nations the government meets part of the bill. Most of the governments list the drugs, which qualify for reimbursement and the extent to which they do so. In most OECD member countries, price is fixed according to the therapeutic value of the drug, its cost of production and the price of similar drugs.

In France and Italy, the manufacturers price must be approved for a product to be reimbursed by the social insurance programme. The UK price system favours domestic firms that would locate corporate headquarters and R&D in UK. Among multinationals it favours those that have significant sales to National Health Service. Further in UK no attempt is made to control the prices of individual drugs. Instead annual arrangements are made with companies to determine the total sum to be paid by the National Health Service for its products. This assures the firms a reasonable rate of return. Germany follows reference pricing of pharmaceuticals. This classifies drugs into groups with similar therapeutic purpose and sets a common reimbursement price for all products within a group. The consumer pays the difference between the reference price and the manufacturers price. Hence demand is highly elastic at above the reference price. In all these countries majority of the people are also covered by some health security schemes.

In the absence of such health security schemes and with the very low purchasing power of the people in India, the government of India has brought certain
essential drugs under the price control. The price control along with the amendment of patent laws in early '70s resulted in a declining impact on prices. Before the amendment of patent laws in India in the '70s, it was reported by Senator Kefauver that 'in drugs, India ranks amongst the highest priced nations of the world' (as quoted in Jhaveri, 1998). Based on our own experience and on a selective comparison of prices of a few drugs in countries where product patents is in force, intellectuals forewarn that the stronger protection would result in increase in the prices of the drugs and thus medicines will be inaccessible to common people. Their comparison of patented drugs introduced elsewhere in the world shows that prices of the drugs had increased manifold after the protection. This fear about the rise in the prices and the probable exploitation by the multinationals among the developing world grew high when the vested multinationals tried to prevail on the South African government to stop the passing of the bill to permit parallel import of the HIV-AIDS drugs which would ensure the availability of those drugs at a lower rate.

The other side of the argument on prices of the drugs is that, developing countries may not be affected by the increase in the price of the drug due to low participation of patented drugs (Watal, 1996; Lanjouw, 1998). This is because so far the dynamic domestic players in India have managed to introduce substitutes of the patented product within four or five years after their appearance in the world market. This 'lag' is to observe, the feed back on the product in the international and other markets (Lanjouw, 1998). Thus, the welfare loss of non-introduction of a patented drug is minimised by the introduction of such drugs though after a lag, so far made possible by the weaker regime, will not be possible in the product patents regime.

One of the major advantages of the universal system is that, it would facilitate access to new medical products. While the welfare loss due to the possible price increase in the post WTO regime is highlighted in most of the studies, the welfare loss due to the non-introduction of new-patented drugs in India due to the weak protection regime is not discussed adequately. In this context, one of the advantages of the product patents is that the stronger patents will provide access to the latest inventions in drugs, which the developed world will not shy away from introducing in India. It is observed that, though Pakistan also has process patent regime, some of the new drugs that were introduced in Pakistan by the
MNCs were not introduced in India at all even though these MNCs were present in the country (Basant, 2000), basically because the MNCs were worried about the domestic industry.

It is also possible that higher prices charged by the MNCs may not really affect the consumers because; the research activities undertaken by the MNCs are totally different and not pertain to the LDC market. Hence it can be said that the percentage of population affected by the price rise would be very less. Sen Gupta (1998) presents a different picture. His analysis shows that prices of `older drugs', which are not patent protected are much higher in India compared to other countries, while prices of drugs that are patent protected or recently off patent are cheaper in India compared to the prices of drugs in the same set of countries. This anomaly he attributes to the price control mechanisms that are in operation in India. Basant's (2000) comparison of various medicines from 14 MNCs operating both in India and Pakistan show that about 70 per cent of the various medicines are cheaper in Pakistan than in India.

There is nothing in the GATT treaty, which prevents India from continuing to use price regulation to protect the consumers against exploitation through high prices. The drug price control mechanisms prevalent in India are applicable on the patented drugs too. Under the Drug Policy (1994) of India, a drug is subject to price control if annual turnover in the audited retail market is more than Rs.40 million. A drug turnover above this minimum revenue level may be exempted if there are at least 5 bulk producers and at least 10 formulators, none with more than 40 per cent of the audited retail market. Any bulk drug with a turnover above Rs.10 million with a single formulator with 90 per cent or more of the market is also subject to price control. Given this last criterion, all patented drugs would be subject to price control, unless they are widely licensed, a highly unlikely scenario (Watal, 1996).

A related issue is the wider use of cost effective generic drugs. In US and some parts of Europe, the pharmacists are authorised to dispense generic drugs in the place of a prescription drugs, which will cost less than the prescription drug. Thus, the consumers have the option to choose between the generic and the branded drug. However, if the doctor writes it as `dispense as written' then the pharmacist cannot change the drug. In India, the `Over the Counter' market is
restricted to a few common medicines and prescriptions bearing the generic name are also uncommon. Unlike the other consumer items, in the case of drugs, the consumer goes by what has been prescribed by the physician. Hence, in the post WTO regime, the physicians will play a crucial role in terms of choosing between a patented drug and a generic drug, in cases where alternatives are available and help the consumers from being exploited by the market forces.

The drug prices, which were brought under control based on the recommendations of the Hathi committee, observed that since the drugs industry has a social responsibility the industry should operate much above the principles of trade for profit. However, due to the repeated plea of the industry that the drug production was becoming unprofitable, in 1986, government reduced the number of drugs under control from 347 to 166. Yet in spite of the price reductions in India, over a period of 15 years from 1980, there has been a general rising trend in prices especially of essential life-saving drugs (Rane, 1995). Recently, while the finance ministry under which the Drug Price Control Order (DPCO) is monitored has announced the decision to reduce the number of drugs under the price control, the report on pharmaceutical pricing set up by the government, after studying the scenario in different countries where some form or the other of price control exists, has recommended that drugs should be under the price control. By the end of 2001, it is likely that the government would reduce the extent of price control to 24 per cent from the current 48 per cent.

Despite the price controls, monitoring and enforcing such prices has been very poor in India (Rane, 1996) where, significant differences persisted between the prices charged by different manufacturers for the same formulation. Mostly companies with substantial market power charged higher prices and the impact of DPCO did not percolate to the consumers at all (Chaudhri, 1996). While stressing the fact that the present price controls will be applicable on patented products too and such controls would definitely benefit the customers, Watal (1996) warns that costs of establishing and maintaining an effective price control over all patented drugs may be very high.

While it is clear from the above arguments that the patented products can be subject to price controls yet it is not very clear, whether the products that enter
the country through the ‘Exclusive Marketing Rights’ (EMR) will also be under these price controls. As per the TRIPS agreement, during the transitional period, developing countries like India will also have to provide ‘Exclusive Marketing Rights’ for products patented elsewhere (any other member country) till the patent application for that product is approved or rejected in India. Kumar (1998) points out that while there is a possibility of getting a product produced locally, if we accept the product patents, under EMR, the import monopoly is sanctioned before examining whether a product is worthy of patent or not. Actually in the TRIPs agreement, the scope and effects of EMRs are not specified. EMR has no legal precedent anywhere in the world but for one case in Argentina. Though as of May 1999, 13 WTO members have notified the establishment of a mailbox like, Argentina, Brazil, Cuba, Egypt, India, Pakistan, Turkey, Uruguay, Kuwait, Morocco, Paraguay, Tunisia and the United Arab Emirates, yet only India and Argentina have gone for EMR. In India no EMR so far has been granted. There is an interesting case of EMR in Argentina. The Argentine patent office confirmed EMR on a US company, since the said application satisfied all the stated conditions. However, the patent examination later revealed that the patent application did not cover a new legal entity but which was already in the public domain and a patent for this product was granted in Luxembourg where patents are granted without prior examination (Correa, 2000).

Hence, to avoid abuse of EMRs, developing countries should ensure that EMRs if granted (a) apply only to new chemical entities, since the rationale of the said

---

3 The TRIPS concept of EMRs appears to have been drawn from US law. The Hatch-Waxman Act of 1984 requires *inter alia* that an innovator drug be granted at least five years of market exclusivity after it is approved by the drug administration before equivalent competing products are approved. This provision was meant to benefit drugs that have either no patent protection or had less than five years patent protection left at the time of approval. Another market exclusivity provision contained in the same law delays generic entry by three years when a new application that requires clinical tests is approved as for instance in the case of a new dosage form of an existing drug or a second use for a known substance. In addition under the Orphan Drug Act, a drug designated as `orphan` drug i.e., one dealing with a rare disease conditions affecting less than 200,000 persons in the US, is entitled to a market exclusivity of seven years. Another sponsor’s application for marketing approval of the same drug for the same use may not be granted during this period of seven years. These provisions in US law first inspired the original US proposals behind Article 39.3 of TRIPS, and later in the TRIPS negotiations, formed the basis for the EMR proposals (Watal, 2001 P.120-121).
article is clearly to provide protection to such entities and not to a simple new form or formulation of a known product and (b) require that a patent in any other WTO Member country that serves as a basis for the EMRs be granted in a country with a serious examination procedure (Correa, 2000). But in the case of drugs EMR should be introduced only after they are certified that the product is suitable to the Indian environment and the consumers. Hence, one way to reduce the monopoly powers enjoyed by such drugs could be to improve the speed of processing the EMR applications and decide on their patent status soon so that domestic controls can be enforced on such drugs.

2.2 Product Patents and Research and Development

One of the advantages of the universal patent regime is that ‘private venture capital firms become willing to invest in technology based start up companies; technical knowledge flows more readily from university laboratories to the market place and local firms become willing to devote substantial resources to internal research’ (Sherwood, 1993). Available evidence show that patents are important for chemicals and particularly for pharmaceuticals basically because of the huge R&D costs incurred by the firms (Nogues, 1990). Also, the purpose of the patent is to provide a form of protection for the technological advances and thereby reward the innovator not only for the innovation but also for the development of an invention up to the point at which it is technologically feasible and marketable. Thus, the number of patents indicates the level of inventive activity and the R&D capabilities of a country. It is a well-known fact that the developing countries’ share in R&D is negligible which also reflects in the number of patents filed by them. 95 per cent of the 16,50,800 patents granted in the US between 1977 and 1996 were conferred upon applications from 10 industrialised countries. The developing countries accounted for less than 2 per cent of the total number of patents (quoted in Correa, 2000). The developing countries R&D declined to about 4 per cent in 1990 from nearly 6 per cent in 1980 despite the steady increase of R&D outlays in Asian newly industrialising countries particularly in South Korea and Taiwan.

The higher cost of the R&D proves to be an effective entry barrier for new firms and hence only firms with large flow of funds become responsible for industrial inventive activity (Grabowski, 1968). In developing countries, only a few firms
have sophisticated R&D facilities and others benefit mainly from the spillovers of the resultant R&D. But, in order to move on to the higher echelon, firms need to invest in R&D. More often small firms shy away from investing in R&D because R&D is based on trial and error. Though small firms are also capable of innovations, for successful commercialization of the innovation, size of the firm matters. For instance, cost of developing one new drug in the US increased from $54 million in 1970 to $231 million in 1990. Recent studies indicate that 1 out of 5000 compounds synthesized during applied research eventually reaches the market. Other estimates indicate that of 100 drugs that enter the clinical testing phase 1, about 70 complete phase 1, 33 complete phase II, and 25-30 clear phase III. Only two-thirds of the drugs that enter phase III is ultimately marketed. This suggests that attrition rates are especially severe in earlier research stages. Compounds that overcome clinical trials of Phase II have a relatively good chance of becoming new drugs. However, as phase III is the more costly R&D stage, one failure out of three produce may still imply a considerable loss of resources’ (Gambardella, 1995). Though global investment in the R&D has been increasing rapidly, R&D efforts need not necessarily result in new products and innovations. According to a US FDA report 84 per cent of new drugs placed on the market by large US firms during the period 1981-88 had little or no potential therapeutic gain over existing drug therapies. Similarly in a study of 775 New Chemical Entities introduced in to the world during the period 1975-89, only 95 were rated to be truly innovative (Lanjouw, 1998).

Because of these reasons and due to the protected policy regime, the R&D investment in India has been very low and started picking up only in the early ‘90s as evident from Table 1. Most of the R&D investment was directed towards

---

4 Phase 1 is for the evaluation of drug safety for clinical pharmacology and toxicity in human volunteers. Phase 2 is for the clinical investigation for treatment effect and phase 3 is the full-scale evaluation of treatment where the drug is administered on several hundred patients and normal subjects. Phase 4 is the post-marketing surveillance to elucidate uncommon side effects.

5 Prior to the ‘90s, the government R&D was much higher than the private R&D (Bowander, 1998; Lakhwinder, 2001), which started changing since the early ‘90s. Of the Rs. 1, 800 crores spent on R&D in 1998, 35 per cent belongs to the public and joint sector and that of the private sector is about 65 per cent (IPR, September, 2000).
process improvements and adapting the technology to local conditions thus resulting in technology spillovers. For instance, the UK multinational Glaxo was faced with several local competitors on the first day when its subsidiary marketed its proprietary drug Ranitidine in India (Lanjouw, 1998), because the competitors enabled by the weaker patent regime were ready with the indigenous version of Ranitidine. The more recent case of adapting the technology developed elsewhere to local conditions enabled by the process patent regime is the case of viagra introduced by Pfizer. A patent for this drug was granted by the US patent office to Pfizer in 1993. The company spent about 13 years and several millions of dollars to develop the drug. Apparently what took Pfizer 13 years and millions of dollars in R&D to perfect, the Indian firms have managed to do in weeks, for a fraction of costs. Of the 30 raw materials used in this drug, 26 are available locally. Utilising the information that was available on the Internet, US patent records and industry literature; some of the Indian firms started their work on the indigenous version of viagra, which was available in the market within weeks of Pfizer formally launching the product. However such reverse engineering is not possible with products that have got patents after 1995. Such absence of stronger protection in the chemical and pharmaceutical sector in developing countries like India is cited as one of the reasons that holds back foreign investment especially from countries like the US, Japan and Germany (Mansfield, 1995). However, with the change in scenario, domestic companies, which had invested in biotechnology, were finding the lack of protection as a problem to commercialise their innovations (Lanjouw, 1998), because in DNA recombinant technologies, novelty is the product. The process of discovery is complicated, but once the product is obtained, its propagation can be achieved in many ways (Reddy and Sigurdson, 1997). However, now factors favour the internationalisation of R&D. The severity of the US regulatory bodies has been one of the strong factors in encouraging US firms to set up R&D and manufacturing facilities else where (OECD, 1985; Kumar, 1996). Recent research done in this area also suggests that besides the level of IPR in a country, factors like the host country’s policy on foreign direct investment, availability of human resources and physical infrastructure, market size, play an important role in the decision to locate the R&D activities by a multinational

---

6 This discussion on Viagra is drawn from Singh Pradeep's article 'Strategic Options in Managing IPRs _ The case of Viagra (Saket Industrial Digest, August, 2001).
enterprise (MNE) in other countries (Kumar, 1996 & 2001). Contrary to the perception that stronger IPR is necessary for attracting R&D investment, an insignificant relationship between the patent protection and location of R&D activity emerges in the analysis of Kumar. On the other hand factors such as availability of technological resources and infrastructure were found to be more important in attracting or improving R&D (Mehrotra, 1989; Kumar, 1996) than the IPR protection. In fact, problems like non availability of basic tools of DNA recombinant technology and lack of technology and expertise among the local recipients to develop diagnostic kits on a mass scale have been faced by units which have set up their R&D facilities in India (Reddy and Sigurdson, 1997). Even in the weaker patent regime of India, MNEs such as Ciba, Hoechst, ICI, Unilever, Cadbury and Astra had set up their R&D, though they protected their innovations by patenting them in their home countries. Basically as Kumar (1996) observes, if the overseas R&D is not directed to new product development but is restricted to local adaptations and providing support to local production of MNE, then IPR will not have much influence on the decision to locate R&D by an MNE.

While the available evidence on product patents impact on R&D is inconclusive, one of the minimum standards mentioned in the TRIPS agreement is that import of a patented product in a host country will be treated as equivalent to producing the same in the host country. Intellectuals strongly oppose this since by allowing such a provision developing countries will not benefit by way of R&D or technology transfer.

Rising R&D costs imply that only giant corporations with formidable R&D, marketing and financial capabilities will be able to afford extensive new drug developments and commercialisations. Since it is difficult for each unit to invest in R&D and to avoid the probable duplication, and economise on scarce R&D resources, pooling of R&D resources and mergers of firms have been identified as possible solutions. Where joint efforts of firms were involved as in the case of Japan, clear logistics have been worked out. 'In Japan the locus of ownership of intellectual property rights flowing from a consortium is determined by the nature and degree of governmental subsidy. Under the hojokin formula, the government provides 40-60 per cent financing, using conditional loans whose repayment are tied to profits. Under the itakusi formula, the government provides full contract financing of research. This formula was used in the case of ICOT, and under this
patents belong to the Ministry of International Trade and Industry, which can be licensed to the members of the consortium and foreign firms’ (Ordover, 1991). Mergers and amalgamations are also taking place to pool the resources and R&D advantages, which reduce the duplication of research and wastage of resources. Hence to avoid such costs and to take advantage of the resources, several consolidations of firms have occurred in the US in the 1980’s. Bristol-Myers and Squibb merged; SmithKline merged with Beecham; American Home Products acquired Robins; Rorer merged with Rhone-Poulenc; Eastman Kodak acquired Sterling Drug, a major drug manufacturer, in 1988; Merrell Dow and Marion Laboratories merged in 1989; in 1990 Hoffmann La Roche acquired 60 per cent of Genetech, one of the few biotechnology companies that succeeded in becoming an integrated pharmaceutical manufacturer. Merck itself set important marketing and research deals with Johnson and Johnson and Dupont, two other giants in the medical and chemical business (Gambardella, 1995).

There has been apprehension about the possible changes in the focus of research in the LDCs in the wake of globalisation to neglect the research that is more relevant for such economies and to indulge in drug discovery that addresses the global diseases. In this context, the concern is will the developing countries such as India benefit by the global R&D efforts or the R&D efforts that might get stimulated within the country? A study done in the context of India observes that of the firms that are both Indian owned and subsidiaries of multinationals, 46.2 per cent of the research funds are targeted at LDC markets. However, they are for products targeted at developing country markets and not for diseases where 99 per cent or more of the burden is on low and middle-income countries.

The patenting activity by the Indian inventors in the US and Europe and other primary data of the study suggest that ‘any discovery research is and would be on global diseases and on products for the worldwide market. But Indian firms are allocating a non-negligible portion of their R&D budgets to tropical diseases research and LDC products and that the fraction of this going towards the discovery of new products, rather than development may well are increasing’ (Lanjouw, 2000).
In view of the importance of the R&D in a knowledge-based industry like pharmaceutical sector, there needs to be a close relationship between the industry and the academic institutes. One of the reasons for the western world’s dominance in R&D is due to the strong research collaboration that exists between the universities and the industry where the research lead provided by the university is taken up for further research by the industry both to explore new areas as well as to work on the existing knowledge available in the public domain. This is very much essential for a country like India, which is opening up now, so that further research is done on areas that are most essential for the welfare of the people. Merck is a US based pharmaceutical company and has a very high in-house expertise. Between 1972 and 1974, Michael S Brown and Joseph L Goldstein of the University of Texas identified the key steps in the production of Cholesterol, work for which they were awarded Nobel Prize in 1985. Their findings motivated Merck’s scientists to launch research on cell culture assays for cholesterol inhibitors as early as 1975. In 1978, Merck isolated Lovastatin the Mevacor compound from a microorganism of the soil. Mevacors NDA was approved for marketing in August 1987. The product reached $260 million sales in 1988, the first full year of marketing and it reached $ 1 billion sales in 1991. As soon as Brown and Goldstein’s discovery was made, it was publicly available. Yet Merck was the only company that effectively exploited their findings (Gamberdalla, 1995). This is a very heuristic illustration. There could be several such findings that may be effectively explored.

Besides patenting the innovations, sound licensing practices are essential to enhance the utility of research done by universities. For instance, University of California at Sanfrancisco and Stanford University jointly hold a patent that covers the technique for combining genetic materials. Rights for this patent were not sold exclusively but were available to any one for a reasonable fee. This patent brought the universities more than $100 million in licensing revenues over the years and has been widely credited with the emergence of the biotechnology industry. On the other hand assigning the rights to one company might have slowed the evolution and commercialisation of biotechnology (Zilberman et al, 2000). A strong collaboration with research institutes and the industry could reduce the research cost in the industry like the expenditure in screening and synthesising the chemicals and the university could provide the research lead. Using US data, Jaffe (1989) found that university research had a positive and
significant effect on corporate patents and industry R&D. He also found that geographical proximity increases the strength of the effect of university research on corporate patents. The contribution of university research is greater if the industry and university scientists can interact more easily (Gabriella, 1995). In India also such strong association between the academic institutes and industry needs to be established. Academic institutes can serve the role of research boutiques where basic research or further research based on knowledge that is available in the public sources may be undertaken and industry can proceed with further development or commercialisation of the compound identified by the university.

2.3 Patents, Foreign Direct Investment and Technology Transfer

One of the expected outcomes of strengthening the IPR is the increase in foreign direct investment (FDI) in R&D, direct manufacturing or joint ventures. However, the impact of stronger patents on FDI remains inconclusive from the available evidence since IPR is only one of the factors in attracting FDI. FDI flows depend on skill availability, technology status, R&D capacity, enterprise level competence and institutional and other supporting technological infrastructure (UNCTAD, 1996; Correa, 2000). Highlighting the FDI flows to countries with allegedly low levels of IPR protection, Correa (2000) observes that the perceived inadequacies of intellectual property protection did not hinder FDI inflows in global terms. Thus FDI increased substantially in Brazil since 1970 until the debt crisis exploded in 1985, while in Thailand FDI boomed during the eighties. In contrast developing countries that had adopted stronger protection have not received significant FDI inflows. He further observes that FDI in the pharmaceutical industry outpaced FDI in most other sectors in Brazil after patent protection for medicines was abolished in that country. In Italy after the introduction of process patent protection in 1978, FDI increased. Hence, it appears that patent production does not have significant impact on FDI. After the abolition of protection on pharmaceuticals in Korea, though no new subsidiary was set up, in the existing companies, the foreign capital had increased and the pharmaceutical industry accounted for 23 per cent of total foreign capital. Foreign investment did increase because, FDI was not allowed in formulations. So the only way to enter the country was to collaborate with a local firm (Kirim, 1985). In the case of India after the adoption of process patents in the pharmaceutical sector, the number of
foreign collaboration increased from 183 in 1970 to 1041 in 1985 (Mehrotra, 1989) perhaps because of the fact they were catering to a larger market.

Kumar (2001) however argues that in developing countries like India, the focus of the FDI policy should be on maximisation of its contribution to the country’s development rather than on increasing the magnitude of inflows. In other words, attracting FDI in specific sectors is more important than aiming at increasing the FDI per se and that alone is not going to improve investments in R&D. Multinational enterprises (MNEs) have so far come to India primarily for exploiting her large domestic market and their contribution to India’s exports is negligible. In contrast, MNEs account for nearly 40 per cent of China’s manufactured exports. During the stronger patent regime before the ‘70s, and after that also, the market share of the MNEs in vitamins and other nutrients was more than 90 per cent while in the case of anti T B drugs it was only 18 per cent (Sen Gupta, 1996).

In the case of India while the total FDI flow has been stagnating, pharma accounts for 1 per cent of total FDI, due to various forms of regulatory framework and the government control over production that was prevalent for a long time. These regulations have been relaxed as part of the liberalisation measures. With a vibrant domestic industry, FDI should improve over a period of time.

**Patents and Technology Transfer**

To qualify for the patent, an invention will have to meet the basic criteria of novelty, non-obviousness and capable of industrial application. As per this, the applicant reveals the content of the patent in the patent application, which is in the public domain. However, such disclosure could undermine the competitive advantage of the invention encouraging the innovator to protect the invention as a trade secret rather than with a patent. For as detailed earlier in the case of Viagra, it is possible to get access to the patent information from the patent office of any of the countries and develop a new product based on the information obtained in the patent application form thanks to the rapid development of information technology. A sizeable level of technology currently available is due to ‘spill overs’ or developing an alternative process that is very close to the existing one. This is the reason why the actual technology in a patent is often
kept as a trade secret (Correa, 2000; Mehrotra, 1989) and which leads to entering into a separate licensing agreement with the innovator for the transfer of that technology.

The high cost of development and rapid obsolescence may prevent the transfer of technology and the patent holder may prefer direct exploitation or import of products than transferring the technology or know-how. Fear of competition also dissuades the transfer of technology or demands a high royalty for the transfer, but huge royalties may have a negative impact on the expenditure on R&D. In the case of India, though in the pre’70s era, the technology transfer by the big TNCs did not support the indigenous technological abilities, yet in the post ’70s, a large number of small and medium size firms have also been transferring their drug technologies to India, thus encouraging an atmosphere of competition in technology transfer (Mehrotra, 1989). But India has encountered difficulties in getting access to technology for a component known as HFC 134 A, which is considered the best available replacement for certain chlorofluorocarbons. Patents and trade secrets cover this technology, and the companies that possess them are unwilling to transfer it without majority control over the ownership of the Indian company (Correa, 2000).

The presence of multinationals did not lead to large-scale technology transfer. Between 1965-1982, top 10 multinationals introduced technology for production of only 9 bulk drugs, while 4 public sector companies introduced technology for 51 bulk drugs and the top Indian private sector companies for 36 drugs. Even in drugs that were open for MNCs, they were not particularly keen to introduce technology in essential drugs (Mehrotra, 1989). In the pharmaceutical industry technological self-reliance can be obtained if bulk drugs are indigenously produced from their basic stage. However, there has been an increase in the manufacturing of bulk drugs from the basic stage onwards since 1991-00, besides the improvements achieved in new drug delivery systems, basic research and development.

3. FLEXIBILITY IN THE TRIPS AGREEMENT

In the foregoing session, the probable impact of product patents on some of the important aspects like prices, R&D, foreign direct investment and technology
inflow was highlighted. Stronger patents because of the exclusive rights effectively rules out competition and ensures the monopoly power of the patent holder throughout the period of protection. The scepticism regarding the access by the developing countries to important breakthroughs in medicine made by the developed countries however linger on. Hence it is feared that it will have adverse effects on trade and may impede the transfer of technology and know-how. However, within the TRIPS Agreement, flexibility is available in the form of compulsory license and exceptions to exclusive rights to increase the access to the drugs or restrict the anti-competitive practices or any other act that would affect the interests of the society at large. The Article 7 of the Agreement states the objectives of the IPR as ‘the protection and enforcement of intellectual property rights should contribute to the promotion of technological innovation and to the transfer and dissemination of technology to the mutual advantage of producers and users of technological knowledge and in a manner conducive to social and economic welfare and to a balance of rights and obligations’. As per this flexibility to define the national laws within the TRIPS framework is available under the clauses of compulsory licensing, exceptions to exclusive rights and the principle of exhaustion, which are discussed below.

A compulsory licensing (CL) system is incorporated in the patents, whereby a person other than the patentee or the government is authorised to produce a patented product. Even under the Paris convention, the provision for CL was there, where a CL cannot be granted before the expiration of four years from the date of filing the application or three years from the date of grant of the patent whichever is longer. But this provision was hardly utilised by the industry because even before the end of the third year of the grant, the process was known. The TRIPS agreement does provide certain grounds (though not limited to them) for a country to exercise the CL option.

The link between IPR and high domestic prices provided the main justifications for weakening the level of protection for drugs by means of comprehensive compulsory licensing practices (Brago in Siebeck et al, 1990). Greece and Yugoslavia have also evolved compulsory licenses. Greece follows renewable license where the first patent lasts for seven years and is renewed if certain conditions are met (OECD, 1985). Canada is one of the countries, which frequently adopted CL to check the price of the patented drugs. In Canada, CL of
products to local firms is encouraged, though the innovating firms view compulsory licensing and renewable patents as restrictions on their rights.

CL in the US has more often been used to restrict the anti competitive practices. CL has been used as a remedy in more than 100 antitrust case settlements. The use of CL \(^7\) is allowed under specific grounds and contains detailed conditions under which a CL can be granted. Like for instance, the CL could be issued under the grounds for (a) refusal to deal by the patent holder, (b) emergency and extreme urgency, (c) anticompetitive practices, (d) non-commercial use, and (e) dependent patents. The TRIPs Agreement does not limit the members right to issue CL only on these grounds. For example, the German patent law has provided that CL could be issued in the interest of public while the Brazilian patent law allows for CL in cases of insufficient working (this is under debate). Though the US is against any country using the CL, and the drug cartel of the US is against the issuance of the compulsory licensing, yet `ironically under the US law, the US’s own patent legislation is far more liberal than that which it is trying to impose on developing countries. Under the US law, if the government wants to use a patent, it can do so without the need for a CL and without negotiating with the patent holder. The patent holder can ask for compensation but has no other rights. In addition, the Bayh Dole Act gives the government wide ranging powers to issue CL’ (Scrip’s Year Book, 2000, Vol.1). In fact, in the US, many compulsory licenses have also been granted in order to remedy anti-competitive practices. In some cases, the licenses have been granted royalty free. `CL has been used as a remedy in more than 100 antitrust case settlements, including cases involving Meprobamate, the antibiotics Tetracycline and Griseofulvin, synthetic steroids and most recently, several basic biotechnology patents owned by Ciba-Geigy and Sandoz, which merged to form Novartis. Statistical analysis of the most important compulsory licensing decrees found that the settlements had no discernible negative effect on the subject companies’ subsequent research and development expenditures, although they probably did lead to greater secrecy in lieu of patenting’ (quoted in Correa, 2000).

Article 40.2 of the TRIPS agreement spells out that `nothing in this Agreement shall prevent Members from specifying in their national legislation licensing

\(^7\) This section draws largely from Correa (2000)
practices or conditions that may in particular cases constitute an abuse of intellectual property rights having an adverse effect on competition in the relevant market. A member may adopt, consistently with the other provisions of this Agreement appropriate measures to prevent or control such practices which may include for example exclusive grant back conditions, conditions preventing challenges to validity and coercive package licensing in the light of the relevant laws and regulations of that member’ (GATT Agreements). In China, ‘any entity which is qualified to exploit the invention or utility model has made requests for authorisation from the patentee of an invention or utility model to exploit its or his patent on reasonable terms and such efforts have not been successful within a reasonable period of time, the patent office may, upon the application of that entity, grant a compulsory license to exploit the patent for invention of utility model’ (as quoted in Keayla, 1994).

Some of the developing countries have argued that working of the patent should not include importation and thus have put forth the case for compulsory licensing of a patented product in the event of `non-working’ in the host country. Watal (2001) however argues that `it is not clear what developing countries hope to achieve by using this condition of local manufacture. It clearly helps domestic industry in getting access to the technology but would this force the pace of transfer of technology? By itself, `working’ requirements are not likely to encourage the transfer of technology, as right holders are not likely to cooperate in giving the required know-how. Where such cooperation is not required, local licenses can be obtained by making `refusal to deal’ or `public interest’ a ground for compulsory licenses, without confronting the non-discrimination clause in Article 27.1. Similarly if the problem is lower prices i.e., to force the use of local labour and materials, thus enabling the manufacturer to offer the patented invention at lower prices, it can also be tackled directly by making the sale of patented inventions on unreasonable terms a ground for compulsory licenses. If `working’ were the only ground for compulsory licenses, by `working’ the patent within three years from its grant, and selling the resultant product at unreasonably high prices for the entire patent term, the right holder saves himself from compulsory licensing’.

Article 30 allows limited exception to patent rights. It states that `members may provide limited exceptions to the exclusive rights conferred by a patent, provided
that such exceptions do not unreasonably conflict with a normal exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties. Accordingly, the following types of exceptions may be provided: `acts done privately and on a non-commercial scale or for a non-commercial purpose; use of the invention for research or teaching purposes; experimentation on the invention to test or improve on it; preparation of medicines under individual prescriptions; experiments made for the purpose of seeking regulatory approval for marketing of a product after the expiration of a patent; use of the invention by a third party that had used it bonafide before the date of application of the patent and importation of patented product that has been marketed in another country with the consent of the patent owner’ (Correa, 2000). Another exception known as Bolar exception also permits the premarket testing of generic products during the patent term, so that they can be marketed immediately upon expiration of the patent.

The other important aspect that is gaining attention is the parallel trade. Objectively, the patent owner loses his rights once the product is on the market or when the patent owner has sold his innovations. This principle is known as the principle of exhaustion of rights or commonly known as parallel trade. TRIPS leave the decision on whether the rights should be exhausted nationally or internationally to national laws. The US adopts a national exhaustion principle whereby the patent owner will have no control over the product once it is placed in the domestic market. But he can exercise his rights outside the US market regarding the price and quantity of the product. The European Union applies the regional exhaustion principle whereby the rights are exhausted within the EU region. International exhaustion gives no right to the patent owner once he has sold his product. The international exhaustion is consistent with the objective of TRIPS agreement mentioned in Article 7. The advantage of international exhaustion is that developing countries such as India can scout for cost advantages of the patented product. Both national and international exhaustion has its own merits and demerits. For instance while the international exhaustion disallows the exclusive rights of the patent owner globally and thus can gain access to the patented product, but an unscrupulous patent owner/manufacturer can restrict the supply of the product that is exported. In those cases exercising the compulsory license option can lead to getting the patented product in
required quantity. Besides, using the international exhaustion, lot of ‘grey’ goods could also be traded.

All these provisions suggest that the patented product can be manufactured, traded and used for experimental purposes, within the provisions of the TRIPS Agreement. The national laws will have to clearly define the cases in which such provisions could be used to benefit the people and the industry.

4. FUTURE SCENARIO OF THE INDIAN PHARMACEUTICAL INDUSTRY

The discussion on prices, R&D and the FDI in the paper highlight that the impact of IPR will largely depend on the developmental status of the economy such as the availability of technical manpower, the capacity of the domestic industry, availability of infrastructure and so on. Thus a stronger regime will bring in more resources in terms of royalty and license fee to the developed countries, whereas the developing countries will have to depend on the developed countries. It is true that in the absence of conclusive evidence on the likely impact of the product patents, a large degree of scepticism prevails for the domestic industry in the developing countries about their functioning in the future. As far as India is concerned, India has a fairly developed pharmaceutical industry, which caters to the domestic as well as the export market. Some of the big units have started strengthening their R&D and have also filed number of applications for patents (Lalitha, 2001) and also there is some evidence available regarding the mergers and amalgamations to pool the human and financial resources (CMIE, 2000) to strengthen the R&D in new product development. These firms will definitely benefit by the stronger protection. Some of the R&D and manufacturing facilities set up in these firms meet the international standards, and they have already been approached by multinationals for conducting research and undertaking manufacturing on their behalf.

Pharmaceutical outsourcing is increasing world over and it is expected that contract research and manufacturing would reach $6.4 and $22.5 billion respectively in 2001 (Scrip’s Year Book, 2000). Hence the domestic units with state of art facilities would derive the maximum benefits. These units could flag off the foreign direct investment in manufacturing and R&D. This segment that has been able to export its products to both developed and developing countries
(Table 2) can widen the market further in the universal patent regime. However, at present the future of the thousands of small units is not very clear. Under normal circumstances, units that are producing the generic drugs should not get affected because these drugs are not patent protected. But it is likely that, they may face competition from large producers who may compete on larger quantity and lower cost of production. Evidence from Jordan indicate that the local industry had to suffer in terms of investment and production and a number of small local firms had to close their operations (Correa, 2000). But the Indian industry has been dynamic and vibrant and most of them work as contract manufacturers too. In future, these units will have to increase the expenditure on marketing and network considerably to withstand the competition. For the section of the industry that has been thriving on the technology spillovers, the good news is that they can continue to do so using the exceptions to exclusive rights and the Bolar exception and aim at producing the generic version of the patented product, which will result in bringing in competition and cost advantages. In this context, it is also essential to protect the innovations that have been introduced by the technology spillovers. Evenson (1990) and Watal (1998) suggest that in order to develop domestic innovations, developing countries require utility models or petty patents. These petty patents can be available for a shorter period of time for process innovations made over an existing product. The TRIPS agreement leaves members to introduce such legislation, as there are no specific rules on this subject. Such patents will encourage the small firms.

One of the concerns regarding the product patents is the access to medicine. In the above mentioned paragraphs some of the provisions within the TRIPS agreement, which clearly says that price controls could be imposed on the patented products. In the recently concluded Doha meeting, a separate declaration on the TRIPS agreement has clarified that members have the right to grant compulsory licence in the area of pharmaceuticals and that they have the freedom to determine the ground upon which such licenses are granted (Economic Times, 2001) which can have a considerable impact on the availability as well as on their prices. In this context, while parallel trade in pharmaceuticals may facilitate access to medicine, it may not actually facilitate flow of technology and R&D, in those cases again compulsory licence will be the only course of option.
However, a majority of the population does not have access to the essential medicines because they are not within their capacity to reach. This necessitates that effective monitoring and implementation of such price control measures need to be put in place. Currently only a handful of pharmaceutical firms in India invest in R&D which needs to be improved. Though all the firms cannot invest in R&D, efforts are required to increase the R&D by those, which have already started investing, and those, which can invest. The pharmaceutical research and development committee (1999) has suggested that a mandatory collection and contribution of 1 per cent of MRP of all formulations sold within the country to a fund called pharmaceutical R&D support fund for attracting R&D towards high cost-low-return areas and be administered by the Drug Development Promotion Foundation. Unlike the western countries India lacks the presence of venture funds or contract research boutiques, which help in providing funds for exploratory projects or undertake the preliminary investigations respectively. However, the domestic universities and other academic institutions can play the role of research boutiques or contract research organisations, which can supply the technical know-how and manpower.

India will have to strengthen the patent examination process and speed up the processing procedures. This will help in checking the products that may enter the country utilising the import monopoly route provided by the EMR. Besides a strong institutional and judicial framework will have to be set up for monitoring the prices, to prevent infringement and trade dress cases respectively. India ranks fifth in the world production of pharmaceutical products and over the years have demonstrated its ability in reverse engineering. It has also registered its presence in the export market and has a relatively developed domestic industry. Hence in the days of WTO regime, one of the strategies could be to utilise the information technology that is fast expanding to new heights to the maximum advantage of the growth of the domestic industry both in off patents and new drug development segment.
Table 1: R&D Expenditure of the Pharmaceutical Industry in India
(Rs. Crores)

<table>
<thead>
<tr>
<th>Year</th>
<th>R&amp;D Expenditure*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1976-77</td>
<td>10.50</td>
</tr>
<tr>
<td>1981-82</td>
<td>29.30</td>
</tr>
<tr>
<td>1986-87</td>
<td>50.00</td>
</tr>
<tr>
<td>1993-94</td>
<td>125.00</td>
</tr>
<tr>
<td>1994-95</td>
<td>140.00</td>
</tr>
<tr>
<td>1995-96</td>
<td>160.00</td>
</tr>
<tr>
<td>1996-97</td>
<td>185.00</td>
</tr>
<tr>
<td>1997-98</td>
<td>220.00</td>
</tr>
<tr>
<td>1998-99</td>
<td>260.00</td>
</tr>
<tr>
<td>1999-00</td>
<td>320.00</td>
</tr>
</tbody>
</table>

Source: Indian Pharmaceutical Industry an Overview, IDMA

Note: * R&D expenditure as per cent of sales 2.0 per cent.

Table 2: Exports of Pharmaceutical Products from India*
(Rs. millions)

<table>
<thead>
<tr>
<th>Country</th>
<th>1995-96</th>
<th>1999-00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Exports</td>
<td>34432</td>
<td>66310</td>
</tr>
<tr>
<td>USA</td>
<td>4238</td>
<td>6718</td>
</tr>
<tr>
<td>Russia</td>
<td>3036</td>
<td>4932</td>
</tr>
<tr>
<td>Hongkong</td>
<td>1919</td>
<td>3562</td>
</tr>
<tr>
<td>Germany</td>
<td>3418</td>
<td>3252</td>
</tr>
<tr>
<td>Nigeria</td>
<td>1199</td>
<td>2577</td>
</tr>
<tr>
<td>UK</td>
<td>1142</td>
<td>2568</td>
</tr>
<tr>
<td>Singapore</td>
<td>868</td>
<td>2452</td>
</tr>
<tr>
<td>Netherlands</td>
<td>1436</td>
<td>2192</td>
</tr>
<tr>
<td>Iran</td>
<td>634</td>
<td>1796</td>
</tr>
<tr>
<td>Brazil</td>
<td>170</td>
<td>1627</td>
</tr>
<tr>
<td>Italy</td>
<td>721</td>
<td>1514</td>
</tr>
<tr>
<td>Vietnam</td>
<td>885</td>
<td>1413</td>
</tr>
<tr>
<td>China</td>
<td>361</td>
<td>1371</td>
</tr>
<tr>
<td>Spain</td>
<td>765</td>
<td>1287</td>
</tr>
<tr>
<td>Srilanka</td>
<td>825</td>
<td>1242</td>
</tr>
<tr>
<td>* Total Exports to top 15 countries</td>
<td>21617</td>
<td>38503</td>
</tr>
</tbody>
</table>

Source: 39th IDMA Annual Publication, 2001
REFERENCES


Express Pharma Pulse, Various Issues, Mumbai


______ (2001), 'WTO Regime, Host Country Policies and Global Patterns of MNE Activity: Recent Quantitative Studies and India’s Strategic Response', *Economic and Political Weekly*, 36(1).


Report of the Pharmaceutical Research and Development Committee (1999), Transforming India into a Knowledge Power, Government of India, New Delhi.


Singh, Pradeep (2001), ‘Strategic Options in Managing IPRs: The Case of Viagra’ Saket Industrial Digest.


